Merck’s Keytruda reduced the risk of death by 38% for patients with RCC
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
An accomplished R&D leader and champion of the application of AI to drug discovery
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Subscribe To Our Newsletter & Stay Updated